Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study

ConclusionsIn this post hoc analysis, eptinezumab use in patients with CM was associated with greater decreases in days with headache with AHM overall and with triptans in particular. The magnitude of effect was greater in the subgroup of CM patients with MOH and  ≥ 50% response.Trial registrationClinicalTrials.gov Identifier:NCT02974153.Graphical abstractEptinezumab reduces headache frequency and acute medication use in patients with chronic migraine.
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research